BRIEF—Synaffix inks China deal worth up to $125 million

Dutch biotech Synaffix, which is exclusively focused on continued advancement of its clinical-stage antibody-drug conjugate (ADC) technology for the development of best-in-class ADCs, has entered into a license agreement with Shanghai Miracogen, a Chinese biotechnology company with a clinical-stage pipeline of ADCs.

Under the terms of the agreement, Miracogen has been granted non-exclusive rights to Synaffix’ proprietary GlycoConnect and HydraSpace ADC technologies for use in its next clinical candidate.

Synaffix is eligible to receive upfront and potential milestone payments that total $125 million, plus royalties.

Miracogen will be responsible for the research, development, manufacturing and commercialization of the ADC product, while Synaffix will be responsible for the manufacturing of components that are specifically related to its proprietary GlycoConnect and HydraSpace technologies.